January 23, 2012 09:08 ET

Market Research Forecasts Cardiovascular Therapeutics Market at $116 Billion by 2017

ROCKVILLE, MD--(Marketwire - Jan 23, 2012) - has announced the addition of the new report "Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success" to their collection of Biotechnology market reports. For more information, visit

Cardiovascular disorders represent a collective group of disorders that affect the functioning of the heart and the blood vessels. These disorders are one the most prevalent groups of disorders in the world today, and represent a significant proportion of the world's total diseased population. Most of them cause significant morbidity and disability.

The global cardiovascular therapeutics market was valued at $93.5 billion in 2010 and expected to reach revenues of $115.6 billion by 2017 with a CAGR of 3.1%. Approximately 127 million patients received pharmacological treatment for their cardiovascular diseases in 2011 with average cost of therapy being $596 per year. In addition, the average annual cost of therapy for the cardiovascular diseases therapeutic area appears likely to increase at a gradual rate over the next one to two years, with an expected price decline in 2011 onwards.

This report details the endpoints in clinical trials for cardiovascular disorders, highlighting the five major cardiovascular disorders, which are atherosclerosis, atrial fibrillation, dyslipidemia, hypertension and venous thromboembolism. The classification of five major cardiovascular diseases is done on the basis of the number of pipeline molecules present in Phase III of development.

The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, such as those related to the effectiveness of treatment as well as other factors. However, endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be important to the objective of the study and represent the most effective way to assess pharmacological response.

For more information, visit

About is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact